Inspra (Eplerenone)

Eplerenone selectively blocks the mineralocorticoid (aldosterone) receptor in the distal nephron of the kidney. By preventing aldosterone binding, it reduces sodium reabsorption and potassium excretion, leading to increased urinary sodium loss, lower blood volume, and decreased blood pressure. In cardiac tissue, the blockade limits aldosterone‑driven fibrosis and remodeling.

The dose of Inspra is individualized by the prescribing healthcare professional based on the patient’s condition, kidney function, serum potassium level, and other clinical factors. The prescriber determines the appropriate starting dose and any subsequent adjustments, and patients should follow the specific instructions provided on their prescription label.

Inspra is classified as Pregnancy Category B, indicating that animal studies have not shown a risk to the fetus, but adequate human data are lacking. It should be used during pregnancy only if the potential benefit justifies any potential risk. Limited data are available for breastfeeding, so a risk‑benefit assessment is required before use.

To order Inspra, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements if applicable) and the necessary import documentation.

Both eplerenone (Inspra) and spironolactone are aldosterone antagonists, but eplerenone is more selective for the mineralocorticoid receptor, resulting in fewer anti‑androgenic side effects such as gynecomastia. Spironolactone may have a broader hormonal profile and is often less expensive, while eplerenone is preferred when patients are sensitive to hormonal side effects.

Inspra tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original packaging to protect from moisture and direct sunlight. Do not store in a refrigerator or freezer, and keep the medication out of reach of children.

Inspra is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

The most serious risks include severe hyperkalemia, which can cause life‑threatening cardiac arrhythmias, and acute kidney injury, especially in patients with pre‑existing renal impairment or when combined with other potassium‑raising agents. Prompt monitoring of serum potassium and renal function is essential to mitigate these risks.

Inspra should be avoided in patients with known hypersensitivity to eplerenone or any component of the formulation, in those with severe renal impairment (eGFR <30 mL/min/1.73 m²), or in individuals with baseline hyperkalemia (serum potassium >5.0 mmol/L). Caution is also advised for patients on concurrent potassium‑sparing medications.